Clinical development of Modified Vaccinia virus Ankara vaccines

Gilbert, Sarah C.

doi:10.1016/j.vaccine.2013.03.020

Cited by 136 publications

(106 citation statements)

References 61 publications

Supporting

Mentioning

102

Contrasting

Order By: Relevance

“…Our data with ChAd63 RH5 add to the growing body of evidence that this simian adenovirus vector is safe for clinical use. Likewise, the clinical safety of MVA as a recombinant vaccine vector for many infectious diseases and cancer is now well documented (57). MVA RH5 appeared to be more reactogenic than the ChAd63 vector at the higher dose, consistent with previous vaccine trials using this orthopoxvirus vector (38,39,43,44,46,58).…”

Section: Discussionsupporting

confidence: 71%

Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions

et al. 2017

View full text Add to dashboard Cite

are named inventors on patent applications relating to RH5 and/or other malaria vaccines and immunization regimens. L. Siani and S. Di Marco are employees of ReiThera (formerly Okairos), which is currently developing vectored vaccines for a number of diseases. J. Vekemans was an employee of GSK, which has acquired the ChAd63 vector from Okairos. R. Ashfield is a director of Ducentis and holds shares in the company, which is developing a therapy for autoimmune disease. A.M. Minassian has an immediate family member who is an inventor on patents relating to RH5 and/or other malaria vaccines and immunization regimens and who is a cofounder of, shareholder in, and consultant for SpyBiotech. S. Biswas is a cofounder and CEO of, and shareholder in, SpyBiotech and is a contributor in a patent application relating to multimerisation technology. J. Jin is a cofounder of and shareholder in SpyBiotech.

show abstract

Section: Discussionsupporting

confidence: 71%

Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions

et al. 2017

View full text Add to dashboard Cite

show abstract

“…At present, MVA serves as one of the most advanced recombinant poxvirus vectors in preclinical research and human clinical trials for developing new vaccines against infectious disease and cancer (12,13,14).…”

mentioning

confidence: 99%

Middle East Respiratory Syndrome Coronavirus Spike Protein Delivered by Modified Vaccinia Virus Ankara Efficiently Induces Virus-Neutralizing Antibodies

Song¹,

Fux²,

Provacia

et al. 2013

J Virol

132

153

View full text Add to dashboard Cite

“…Thus the use of MVA in humans is completely safe. Other advantages of MVA are that it is genetically stable, very immunogenic, and easy to manufacture [113,114]. The MVA immunogenic potential for cytotoxic responses is due in part to uptake of dying vaccinia virus-infected cells by antigenpresenting cells and cross-presentation of antigens to CD8+ T cells [115].…”

Section: Recombinant Virusmentioning

confidence: 99%

Prophylactic and Therapeutic Vaccines against Human Papillomavirus Infections

Rosales¹,

Rosales²

2017

Vaccines

View full text Add to dashboard Cite

Human papillomaviruses (HPVs) are a large family of double-strand DNA viruses comprising more than 180 types. Infection with HPV is associated with benign and malignant proliferation of skin and mucosae. Low-risk HPVs produce warts, whereas high-risk viruses induce tumors. Because there are no anti-viral drugs for HPV infection, there is a lot of interest in vaccines that can prevent the infection and also in vaccines that can be used to treat established infections and HPV-related tumors. Two prophylactic vaccines have been approved for preventing HPV infection. They seem to be efective when very young people are vaccinated. Unfortunately, many older people are still at risk of infection, mainly in countries where vaccination coverage is not eicient and for those people, novel therapeutic vaccines are being developed. This chapter describes the properties of HPV vaccines used today and the current status of several therapeutic vaccines been developed to treat HPV-induced lesions.

show abstract

Clinical development of Modified Vaccinia virus Ankara vaccines

Cited by 136 publications

References 61 publications

Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions

Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions

Middle East Respiratory Syndrome Coronavirus Spike Protein Delivered by Modified Vaccinia Virus Ankara Efficiently Induces Virus-Neutralizing Antibodies

Prophylactic and Therapeutic Vaccines against Human Papillomavirus Infections

Contact Info

Product

Resources

About